Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Non Operating Income (2017 - 2025)

Historic Non Operating Income for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Q3 2025 value amounting to $12.5 million.

  • Crinetics Pharmaceuticals' Non Operating Income rose 1391.19% to $12.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.8 million, marking a year-over-year increase of 6329.93%. This contributed to the annual value of $40.9 million for FY2024, which is 20817.2% up from last year.
  • As of Q3 2025, Crinetics Pharmaceuticals' Non Operating Income stood at $12.5 million, which was up 1391.19% from $13.5 million recorded in Q2 2025.
  • In the past 5 years, Crinetics Pharmaceuticals' Non Operating Income registered a high of $14.6 million during Q1 2025, and its lowest value of -$68000.0 during Q3 2021.
  • Moreover, its 5-year median value for Non Operating Income was $2.5 million (2022), whereas its average is $5.5 million.
  • As far as peak fluctuations go, Crinetics Pharmaceuticals' Non Operating Income tumbled by 15190.84% in 2021, and later surged by 1822142.86% in 2022.
  • Quarter analysis of 5 years shows Crinetics Pharmaceuticals' Non Operating Income stood at $14000.0 in 2021, then soared by 18221.43% to $2.6 million in 2022, then surged by 163.63% to $6.8 million in 2023, then surged by 109.26% to $14.2 million in 2024, then decreased by 11.7% to $12.5 million in 2025.
  • Its last three reported values are $12.5 million in Q3 2025, $13.5 million for Q2 2025, and $14.6 million during Q1 2025.